282 related articles for article (PubMed ID: 20012564)
1. Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.
Eissa S; Zohny SF; Zekri AR; El-Zayat TM; Maher AM
Med Oncol; 2010 Dec; 27(4):1286-94. PubMed ID: 20012564
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
3. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
[TBL] [Abstract][Full Text] [Related]
4. Urinary retinoic acid receptor-β2 gene promoter methylation and hyaluronidase activity as noninvasive tests for diagnosis of bladder cancer.
Eissa S; Zohny SF; Shehata HH; Hegazy MG; Salem AM; Esmat M
Clin Biochem; 2012 Apr; 45(6):402-7. PubMed ID: 22286019
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Mitropoulos D; Botsoli-Stergiou E; Constantinides C; Giannopoulou M; Choremi-Papadopoulou H
Urology; 2000 Jun; 55(6):871-5. PubMed ID: 10840098
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic evaluation of urinary angiogenin (ANG) and clusterin (CLU) as biomarker for bladder cancer.
Shabayek MI; Sayed OM; Attaia HA; Awida HA; Abozeed H
Pathol Oncol Res; 2014 Oct; 20(4):859-66. PubMed ID: 24696417
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.
Abd El Gawad IA; Moussa HS; Nasr MI; El Gemae EH; Masooud AM; Ibrahim IK; El Hifnawy NM
J Egypt Natl Canc Inst; 2005 Sep; 17(3):193-202. PubMed ID: 16799657
[TBL] [Abstract][Full Text] [Related]
8. The clinical relevance of urine-based markers for diagnosis of bladder cancer.
Eissa S; Swellam M; Amin A; Balbaa ME; Yacout GA; El-Zayat TM
Med Oncol; 2011 Jun; 28(2):513-8. PubMed ID: 21437743
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic significance of protein NMP22 in bladder cancer].
Rybotycka Z; Długosz A
Pol Merkur Lekarski; 2015 Jun; 38(228):309-14. PubMed ID: 26098648
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of urinary molecular markers in bladder cancer.
Eissa S; Swellam M; el-Mosallamy H; Mourad MS; Hamdy NΜ; Kamel K; Zaglol AS; Khafagy MM; el-Ahmady O
Anticancer Res; 2003; 23(5b):4347-55. PubMed ID: 14666650
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of bladder cancer by analysis of urinary fibronectin.
Menéndez V; Fernández-Suárez A; Galán JA; Pérez M; García-López F
Urology; 2005 Feb; 65(2):284-9. PubMed ID: 15708039
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
[TBL] [Abstract][Full Text] [Related]
13. Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer.
Eissa S; Zohny SF; Swellam M; Mahmoud MH; El-Zayat TM; Salem AM
Clin Biochem; 2008 Nov; 41(16-17):1335-41. PubMed ID: 18804101
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of urinary HURP mRNA as a marker for detection of bladder cancer: relation to bilharziasis.
Eissa S; Matboli M; Mansour A; Mohamed S; Awad N; Kotb YM
Med Oncol; 2014 Feb; 31(2):804. PubMed ID: 24375315
[TBL] [Abstract][Full Text] [Related]
15. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer.
Eissa S; Labib RA; Mourad MS; Kamel K; El-Ahmady O
Eur Urol; 2003 Dec; 44(6):687-94. PubMed ID: 14644121
[TBL] [Abstract][Full Text] [Related]
16. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
17. Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer.
Leyh H; Mazeman E
Eur Urol; 1997; 32(4):425-8. PubMed ID: 9412800
[TBL] [Abstract][Full Text] [Related]
18. Human complement factor H related protein test for monitoring bladder cancer.
Raitanen MP; Marttila T; Nurmi M; Ala-Opas M; Nieminen P; Aine R; Tammela TL;
J Urol; 2001 Feb; 165(2):374-7. PubMed ID: 11176376
[TBL] [Abstract][Full Text] [Related]
19. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
[TBL] [Abstract][Full Text] [Related]
20. Significance of the BTA test in bladder cancer: a multicenter trial. BTA Study Group Japan.
Miyanaga N; Akaza H; Kameyama S; Hachiya T; Ozono S; Kuroda M; Koga H; Koiso K
Int J Urol; 1997 Nov; 4(6):557-60. PubMed ID: 9477183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
